A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric Cancer
Phase of Trial: Phase III
Latest Information Update: 11 Mar 2019
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Biomarker; Therapeutic Use
- Acronyms START 2
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Primary endpoint (Relapse-free survival rate (3-years recurrence free survival rate)) has been met, according presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.